Lundbeck And Axsome Rival Candidate Data Raise Prospects For First Alzheimer’s Agitation Approvals
Filings On The Horizon?
The firms unveiled positive Phase III data from their respective assets for treating the agitation seen in Alzheimer’s disease with Lundbeck’s candidate set to become first-to-market for the challenging behavioral symptom.
You may also be interested in...
The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.
Recent executive moves in the industry include C-suite changes at Fresh Tracks Therapeutics and Protara Therapeutics. Meanwhile, new directors were appointed at Grey Wolf Therapeutics and BioSenic.
The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.